drugset / Trial / NCT05359783

Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide

NCT05359783 ↗

Phase 1/2 Completed 50 enrolled Vastra Gotaland Region
NaSingle-groupOpen-labelTreatment

Summary

Sentinel lymph node (SLN) status is pivotal for treatment decisions in breast cancer patients. The dual technique with Technetium99m (Tc99) and blue dye (BD) is yet the current routine for SLN detection. However, the same reliability has been presented by superparamagnetic iron oxide nanoparticles (SPIO). The aim of this study was to determine if SLN detection using ultra-low dose SPIO is feasible.

Timeline

Start
2021-11-01
Primary completion
2023-02-15
Completion
2024-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Superparamagnetic Iron Oxide Diagnostic / imaging agent 0.1 ml Other
Subject Superparamagnetic Iron Oxide Diagnostic / imaging agent 0.25 ml Other
Subject Superparamagnetic Iron Oxide Diagnostic / imaging agent 0.5 ml Other

Indications